Urokinase
CAS No. : 9039-53-6 (Plasminogen activator;fibrinolytic; enzyme)

CAS No.: 9039-53-6
Complies with CP2020, JP18, BP2023, EP11.0

Indications

The product is mainly used for thrombolytic therapy of thromboembolic diseases. These include acute generalized pulmonary embolism, coronary artery embolism and myocardial infarction within 6-12 hours of chest pain, acute cerebrovascular embolism with symptoms shorter than 3-6 hours, retinal artery embolism and other peripheral artery embolism symptoms of severe skeletal vein thrombosis. It is also used to prevent thrombosis after prosthetic heart valve surgery, and to keep vascular cannulation and thoracic and pericardial drainage tubes unobstructed. Thrombolytic efficacy requires subsequent heparin anticoagulation to maintain.

The product is an enzyme thrombolytic drug, which can activate the conversion of plasminogen into plasmin in the body, thereby hydrolyzing fibrin to dissolve the freshly formed thrombus. For acute myocardial infarction, acute cerebral thrombosis and cerebral vascular embolism, perilimb arteriovenous thrombosis, central retinal arteriovenous thrombosis and other fresh thrombo occlusive diseases. The product has no obvious effect on old thrombosis. It is also suitable for the treatment of cerebral thrombosis, peripheral vascular embolism, central retinal vascular embolism, acute myocardial infarction and other fresh thromboembolic diseases, as well as kidney transplantation, plastic surgery and other thrombosis, all have good efficacy.